Inogen Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Inogen Inc (INGN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Inogen Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 354M vs 9,209M combined for its competitors (3.7% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+7.3% annualized vs trailing 12 months), vs decelerating (-2.4%) for its tracked peer group.
- Growth: Inogen Inc generated 3.0% revenue growth year over year in Q2 2026, vs 3.3% for its competitors combined.
- Profitability: Its -4.1% net margin compares with 12.0% for the peer group.
- Scale: Inogen Inc ranks #109 of 246 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.0% of industry market cap.
- Peer revenue share: Inogen Inc accounted for 4.1% of combined revenue among its tracked peer group, down from 4.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.47M compares with $0.29M for the peer group (1.6x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
INGN Sales vs. its Competitors, Q2 2026
Inogen Inc reported revenue growth of 3.04 % year on year in Q2 2026, below its competitors' combined revenue growth of 3.26 %.
With a net margin of -4.05 %, Inogen Inc reported lower profitability than its competitors (12.02 %).
Inogen Inc generated 4.06 % of the combined sales of its peer group, down from 4.07 % a year earlier.
Inogen Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Inogen Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Inogen Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Inogen Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Inogen Inc's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 14.8% year over year, combined, vs 3.0% for Inogen Inc. Inogen Inc's share of combined industry revenue moved from 0.09% to 0.08%, a loss of 0.01 percentage points.
Inogen Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Inogen Inc | No | Yes | No | No |
| Competitors combined (8) | ||||
| High-Confidence Competitors (6) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
INGN Stock Performance relative to its Competitors
INGN Stock Performance relative to High-Confidence Competitors
INGN Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Electromed Inc | 282.9% | Outperformed |
| 2 | Profound Medical Corp | 282.9% | Outperformed |
| 3 | Amedisys Inc | 282.9% | Outperformed |
| 4 | Koninklijke Philips Nv | 282.9% | Outperformed |
| 5 | Resmed Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Inogen Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Inogen Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Inogen Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Inogen Inc |
185.53 | 354.30 |
 Resmed Inc |
32,975.93 | 5,743.16 |
 Koninklijke Philips Nv |
25,910.59 | 20,163.51 |
 Amedisys Inc |
3,361.86 | 2,402.37 |
 Adapthealth Corp |
790.86 | 3,226.71 |
 Profound Medical Corp |
238.82 | 19.09 |
| SUBTOTAL | 63,784.80 | 32,129.10 |
Sign in to see all competitors of Inogen Inc .
Sources: Inogen Inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Inogen Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Inogen Inc's Competitors Named by the Company
Competitive relationships identified from Inogen Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Accendra Health inc | Company report | 85% |
| Caire Medical | Company report | 85% |
| Koninklijke Philips N.V. | Company report | 85% |
| Precision Medical | Company report | 85% |
| SysMed | Company report | 85% |
| Drive DeVilbiss Healthcare | Company report | 85% |
| Nidek Medical Products | Company report | 85% |
| Respironics | Company report | 85% |
| 3B Medical | Company report | 85% |
| GCE Healthcare | Company report | 85% |
| React Health | Company report | 85% |
| O2 Concepts | Company report | 85% |
| Rhythm Healthcare | Company report | 85% |
| NGK Spark Plug | Company report | 85% |
| Gas Control Equipment | Company report | 85% |
| Belluscura | Company report | 85% |
| Colfax | Company report | 85% |
| Drive Medical | Company report | 85% |
| iRhythm Technologies, Inc. | Company report | 85% |
| DeVilbiss Healthcare | Company report | 85% |
| Nidek Medical | Company report | 85% |
| OMI | Company report | 85% |
| Resmed | Company report | 85% |
| Invacare Corporation | Company report | 85% |
| Medtronic | Company report | 85% |
| Ventec Life Systems | Company report | 85% |
| Breas Medical | Company report | 85% |
| Bellascura | Company report | 85% |
| Hill-Rom Holdings, Inc. | Company report | 85% |
| Adapthealth Corp | Company report | 85% |
| Electromed Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Inogen Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Inogen Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Inogen Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Resmed Inc | Devices 49.96 % |
| Adapthealth Corp | Sleep Health 52.20 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Inogen Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Inogen Inc | 186 | 470,523 | -32,663 |
| Resmed Inc | 32,976 | 505,116 | 140,120 |
| Koninklijke Philips Nv | 25,911 | 294,706 | 14,823 |
| Amedisys Inc | 3,362 | 126,440 | 4,309 |
| Adapthealth Corp | 791 | 296,028 | -20,493 |
| Profound Medical Corp | 239 | 117,815 | -103,648 |
| PEERS TOTAL | 63,599 | 288,094 | 22,840 |
Inogen Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Inogen Inc | US 56.61 % |
| Resmed Inc | Combined Europe Asia and other markets 31.05 % |
| Profound Medical Corp | CA 66.91 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Inogen Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 218 companies in Inogen Inc's industry classification, broader than the peer set above. Market cap in millions of $.Inogen Inc ranks #109 of 218 companies by market capitalization in its industry, holding 0.02 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 600, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 154,357 | 13.55 % |
| 2 | Medtronic Plc | 124,064 | 10.89 % |
| 3 | Stryker Corp | 112,658 | 9.89 % |
| 4 | 3m Company | 91,075 | 8.00 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Becton Dickinson And Company | 1,234 | 5.2% |
| 7 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 8 | Alcon inc | 1,234 | 5.2% |
| 9 | Resmed Inc | 1,234 | 5.2% |
| 10 | Dexcom Inc | 1,234 | 5.2% |
| 109 | Inogen Inc | 186 | 0.02 % |
Market cap and industry share for the rest of Inogen Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-10-30.
Inogen Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 104 | Utah Medical Products Inc | 217 | 17.74 % |
| 105 | Trisalus Life Sciences Inc | 216 | -19.83 % |
| 106 | Rxsight Inc | 202 | -41.40 % |
| 107 | Mobia Medical Inc | 202 | - |
| 108 | Pro dex Inc | 1,234 | 12.3% |
| 109 | Inogen Inc | 186 | -16.77 % |
| 110 | Solana Company | 1,234 | 12.3% |
| 111 | Neuronetics Inc | 1,234 | 12.3% |
| 112 | Axe Compute Inc | 1,234 | 12.3% |
| 113 | Fractyl Health Inc | 1,234 | 12.3% |
| 114 | Koru Medical Systems Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Inogen Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-10-30. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Inogen Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (320 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.45 % | 24.79 % (avg) | -24.3 pp |
| Operating Margin | -0.08 % | industry median | 0.0 pp |
| EBITDA Margin | 0.01 % | -5.38 % (avg) | +5.4 pp |
| Capital Intensity (Capex / Revenue) | 0.70 % | 6.27 % (avg) | -5.6 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Inogen Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (320 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 8.3x | 36.5x | -28.2x |
| EV / EBITDA | 19.0x | 18.1x | +1.0x |
| P/B | 1.0x | 4.6x | -3.7x |
| Return on Equity | -0.13 % | industry aggregate | -12.11 % |
| Return on Invested Capital | - | -4.56 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Inogen Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 43.57 % | 1.07 % | -14.77 % | 16.05 % | 5.37 % | -16.32 % | 6.35 % | 3.86 % |
| Operating Margin | 10.58 % | 5.47 % | -3.90 % | 2.58 % | -22.60 % | -34.65 % | -12.66 % | -8.66 % |
| Return on Invested Capital | 6.58 % | 2.79 % | -1.59 % | 1.15 % | -11.63 % | -20.20 % | -10.18 % | -6.76 % |
| P/E | 61.3x | 68.8x | - | - | - | 1.2x | 6.2x | 8.9x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Inogen Inc's BCG Growth-Share Matrix
Relative market share (vs Inogen Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Inogen Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.5% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Inogen Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 600 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.70 % vs industry average 6.27 % (see Profitability & Cost Structure above) |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments. Supplier power and buyer power are not assessed here -- see Inogen Inc's dedicated Suppliers and Customers pages for concentration data; threat of substitutes has no systematic data source in this system and is not estimated.
Inogen Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Inogen Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Inogen Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+7.3% annualized vs trailing 12 months).
Weaknesses
- Return on equity 12.1 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-2.4% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Inogen Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Inogen Inc | 1.50 | 3.02 | - |
| Resmed Inc | 1.05 | 3.03 | 0.10 |
| Koninklijke Philips Nv | 0.37 | 1.32 | 0.73 |
| Amedisys Inc | 0.59 | 1.27 | 0.30 |
| Adapthealth Corp | - | 1.04 | 1.19 |
| Profound Medical Corp | 4.84 | 6.88 | 0.15 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Inogen Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Inogen Inc | Q2 2026 | +3.0 % | - |
| Resmed Inc | Q3 2026 | +8.7 % | +20.0 % |
| Koninklijke Philips Nv | Q4 2025 | +3.4 % | - |
| Amedisys Inc | Q2 2025 | +5.2 % | -10.8 % |
| Adapthealth Corp | Q2 2026 | -7.5 % | - |
| Profound Medical Corp | Q2 2026 | +12.3 % | - |
| PEERS TOTAL | +3.4 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Inogen Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Inogen Inc | Q2 2026 | +1.7 % | +3.9 % |
| Resmed Inc | Q3 2026 | +5.1 % | +13.4 % |
| Koninklijke Philips Nv | Q4 2025 | +4.6 % | -11.3 % |
| Amedisys Inc | Q2 2025 | +6.6 % | -41.1 % |
| Adapthealth Corp | Q2 2026 | +22.0 % | +87.5 % |
| Profound Medical Corp | Q2 2026 | -9.6 % | - |
Inogen Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Inogen Inc | - | - | - |
| Resmed Inc | 18.67% | 21.10% | 25.50% |
| Koninklijke Philips Nv | 3.21% | 3.86% | 7.86% |
| Amedisys Inc | 3.77% | 4.60% | 6.68% |
| Adapthealth Corp | - | - | - |
| Profound Medical Corp | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Inogen Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Inogen Inc | 8.58 | 0.52 |
| Resmed Inc | 20.96 | 5.74 |
| Koninklijke Philips Nv | 28.95 | 1.29 |
| Amedisys Inc | 39.30 | 1.40 |
| Adapthealth Corp | - | 0.25 |
| Profound Medical Corp | 2.40 | 12.51 |
| PEERS AVERAGE | 25.57 | 1.99 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.